HC Wainwright set a $22.00 price objective on Iovance Biotherapeutics (NASDAQ:IOVA) in a research report released on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the stock. ValuEngine upgraded shares of Iovance Biotherapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a hold rating to a buy rating and set a $8.25 target price for the company in a report on Tuesday, October 17th. Oppenheimer set a $13.00 target price on shares of Iovance Biotherapeutics and gave the stock a buy rating in a report on Tuesday, October 31st. BidaskClub upgraded shares of Iovance Biotherapeutics from a buy rating to a strong-buy rating in a report on Friday, February 2nd. Finally, B. Riley restated a buy rating and issued a $18.00 target price on shares of Iovance Biotherapeutics in a report on Monday, November 13th. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $18.75.

Iovance Biotherapeutics (IOVA) opened at $16.80 on Thursday. Iovance Biotherapeutics has a 12-month low of $4.45 and a 12-month high of $18.15.

Several institutional investors have recently added to or reduced their stakes in IOVA. Schwab Charles Investment Management Inc. bought a new stake in shares of Iovance Biotherapeutics in the 2nd quarter worth about $1,538,000. Bank of New York Mellon Corp bought a new stake in Iovance Biotherapeutics during the 2nd quarter valued at about $1,796,000. Legal & General Group Plc bought a new stake in Iovance Biotherapeutics during the 2nd quarter valued at about $103,000. Swiss National Bank bought a new stake in Iovance Biotherapeutics during the 2nd quarter valued at about $655,000. Finally, Wells Fargo & Company MN bought a new stake in Iovance Biotherapeutics during the 2nd quarter valued at about $528,000. Hedge funds and other institutional investors own 65.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give Iovance Biotherapeutics (IOVA) a $22.00 Price Target” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/11/hc-wainwright-analysts-give-iovance-biotherapeutics-iova-a-22-00-price-target.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.